May Liu - Anthera Pharmaceuticals SVP
SVP
Ms. May Liu has is Senior Vice President Finance and Administration, Principal Accounting Officer of Anthera Pharmaceuticals, Inc. Ms. Liu has served as our Senior Vice President, Finance and Administration since June 2013 and as our Principal Accounting Officer since May 2013. Prior to that, she served as our Vice President, Finance from January 2011 to June 2013, and as our Corporationrationrate Controller from October 2007 to January 2011. Ms. Liu joined us as our Director of Finance in April 2007. Prior to joining us, Ms. Liu served as SEC Reporting and Technical Accounting Manager at Renovis, Inc., a clinicalstage pharmaceutical company, from October 2005 to March 2007. Ms. Liu was a Certified Public Accountant since 2007 and was a part of Ernst Young LLPs audit and assurance practice from 2000 to 2005, focusing primarily in the life science industry since 2013.
| Age | 47 |
| Tenure | 12 years |
| Phone | 410 350 1839 |
| Web | https://www.anthera.com |
Anthera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.4196) % which means that it has lost $1.4196 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.6885) %, meaning that it created substantial loss on money invested by shareholders. Anthera Pharmaceuticals' management efficiency ratios could be used to measure how well Anthera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas. Anthera Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 21 people. Anthera Pharmaceuticals [ANTH] is a Pink Sheet which is traded between brokers over the counter. Anthera Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.Management Performance
| Return On Equity | -5.69 | ||||
| Return On Asset | -1.42 |
Anthera Pharmaceuticals Leadership Team
Elected by the shareholders, the Anthera Pharmaceuticals' board of directors comprises two types of representatives: Anthera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anthera. The board's role is to monitor Anthera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Anthera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anthera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bradley Esq, Sec | ||
| May Liu, Principal Accounting Officer, Compliance Officer and Sr. VP of Fin. and Admin. | ||
| Paul Adams, VP Compliance | ||
| Joshua Caldwell, Chief Officer | ||
| MBA MBA, Ex Chairman | ||
| Charles DSc, Advisor | ||
| Klara DickinsonEason, Advisor | ||
| John Thompson, CEO Director |
Anthera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Anthera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.69 | ||||
| Return On Asset | -1.42 | ||||
| Current Valuation | (7.47 M) | ||||
| Shares Outstanding | 26.18 M | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Earning | (0.20) X | ||||
| Price To Book | 0.11 X | ||||
| Gross Profit | (28.49 M) | ||||
| EBITDA | (26.59 M) | ||||
| Net Income | (26.87 M) |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Anthera Pink Sheet
If you are still planning to invest in Anthera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Anthera Pharmaceuticals' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |